![](http://www.epa.gov/epafiles/images/epafiles_misc_space.gif) |
![](http://www.epa.gov/epafiles/images/epafiles_misc_space.gif) |
EDRI Federal Project Inventory:
58223-04 Spore in Breast Cancer
- Sponsor Organization: NIH/NCI
- Project Title: 58223-04 SPORE IN BREAST CANCER
- Project Focus: HUMAN HEALTH EFFECTS
- Description: We propose to continue the Carolina Breast Cancer Study, a population-
based, case-control study that integratesmolecular biology and
epidemiology in the search for causes of breast cancer. Participants
will include 20-74-year-oldwomen residing in a 24-county area of
central and eastern North Carolina. Cases will be women diagnosed
withinvasive or in situ breast cancer for the first time between
cases by sex, race, and age +/-5 years) and will be identified using
computerized lists from the NorthCarolina Division of Motor Vehicles
for women 20-64 years old and from the U.S. Health Care
FinancingAdministration for women 65-74 years old. By the end of the
funding cycle, data from 1600 women with invasive breastcancer and an
equal number of appropriate controls will be available. Sampling will
insure that approximately 50113fcases and controls are African-
American. Information on established and hypothesized breast cancer
risk factors will beobtained by personal interview. Blood samples for
extraction of germline DNA will be collected from all
consentingparticipants, and paraffin-embedded tumor specimens will be
requested for all breast cancer cases. Medical records willbe
obtained to document treatment, stage, and prognostic characteristics
to supplement descriptions available frompathology review of H&E
slides of the breast tumor. The epidemiologic and clinical data and
biological specimens willprovide the basic resources necessary to
address the relative contributions of genes and environment to
breastcarcinogenesis. The scientific questions of particular interest
in this proposal are: 1) to what extent inheritedsusceptibility to
breast cancer at various loci (BRCA1, BRCA2, MSH2) contributes to
breast cancer, whether somaticalterations at the same loci are
involved in sporadic disease, and which environmental/behavioral
factors influencepenetrance/somatic occurrence of the disease
mutations; 2) whether specific, somatic, molecular
alterations(amplification of HER-2/neu, PRAD1/EMS1, c-MYC, or 20q, p53
alterations, LOH at 17q21) can serve as signaturesfor etiologically-
distinct subsets of breast cancer, and if so, which environmental,
behavioral exposures increase risk oftheir occurrence; 3) whether
specific alleles at P450 or other metabolic loci modulate effects of
environmental exposureson breast cancer risk; and 4) whether racial
differences in breast cancer among African-American and Caucasian
womencan be explained by specific molecular alterations or
constellations of risk factors.
- References:
- Category: MEASUREMENTS
- Subcategory: EXPOSURE AND RISK MODELS
- Keywords for Experimental System/Species: HUMAN, FIELD STUDY
- Keywords for Experimental Endpoints: CARCINOGENESIS, MOLECULAR, EXPOSURE MONITORING, EPIDEMIOLOGY,
CYTOCHROME P450
- Chemical Agents: ESTROGEN, ORAL CONTRACEPTIVES
- Performing Institution: UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
- Contact: CONTACT PERSON:ELAINE C. LEE; BUILDING 31; 11A21, NATIONAL CANCER
INSTITUTE, NIH,BETHESDA, MD 20892-2590; 301 496-5515;
LEEE@0D.NCI.NIH.GOV
|
|